• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Genentech

Genentech

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Genentech Provides Update on Phase III Study of Gazyva® in People With Previously Untreated Diffuse Large B-Cell Lymphoma

    Genentech Provides Update on Phase III Study of Gazyva® in People With Previously Untreated Diffuse Large B-Cell Lymphoma

  2. Genetic Testing Market Forecast (2016-2021) - Increased Demand For Testing Services in Evolving Healthcare Community - Research and Markets

    Genetic Testing Market Forecast (2016-2021) - Increased Demand For Testing Services in Evolving Healthcare Community - Research and Markets

  3. Ethris Adds Three New Members to its Board of Directors

    Ethris Adds Three New Members to its Board of Directors

  4. Global Immune Check Activators Competitive Landscape, Technology and Pipeline Analysis, 2016 - Research and Markets

    Global Immune Check Activators Competitive Landscape, Technology and Pipeline Analysis, 2016 - Research and Markets

  5. Dendrimers and Polymer Drug Conjugates Market (2016 - 2026) - 40 Polymer Drug Conjugates in Clinical Development - Research and Markets

    Dendrimers and Polymer Drug Conjugates Market (2016 - 2026) - 40 Polymer Drug Conjugates in Clinical Development - Research and Markets

  6. Social Security Tips For Couples

    Genentech DNA reported strong first-quarter revenue and earnings growth compared with the year-ago period, and we are sticking with our fair value estimate. As the company warned at its investor meeting in March, quarter-over-quarter product sales growth was stagnant, while total revenue growth ...

  7. Tuttle Tactical Management Weekly Market Commentary

    Genentech DNA continues to focus attention on its commercial lineup, making its slimmer early-stage pipeline not worrisome yet. The biotech firm has additional clinical trials and hopes to expand indications for each of its largest products, including Avastin, Herceptin, and Rituxan. According to ...

  8. Roche Builds a Wide Moat With Dominant Oncology and Diagnostics Franchises

    Firm has a promising strategy of combining expertise in both areas to generate a growing personalized medicine pipeline.

  9. Reinvent Your Practice: Alternatives to Traditional Succession Planning

    Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.